Why the study?
Does anthracycline therapy without cardioprotection lead to significant LVEF decline in patients?
Does anthracycline therapy without cardioprotection lead to significant LVEF decline in patients?
While overall LVEF decline after anthracyclines without cardioprotection is small, a subset of patients experiences significant impairment, highlighting the need for targeted cardioprotective strategies.
Answers are grounded in this paper and cite their sources.
Does not support routine cardioprotection in all anthracycline recipients; leaves open targeted strategies for vulnerable subsets.
While the mean LVEF decline in patients without cardioprotective therapy was clinically small, a vulnerable subset experienced significant impairment. Further research to best identify those who benefit most from cardioprotective therapies when receiving anthracyclines is required.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: